Actifed

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Actifed

What is Actifed? Quick Facts

Property Description
Active Ingredients Pseudoephedrine, Triprolidine
Form Oral Solid (Tablet/Capsule), Oral Liquid (Syrup)
Pharmacological Class Sympathomimetic Amine & First-generation H1 Antagonist
Common Use Upper Respiratory Congestion, Allergic Rhinitis
Origin Synthetic, Fixed-Dose Combination

What Type of Medicine Is Actifed? (Composition and Classification)

Actifed is defined as a synthetic, fixed-dose combination product for oral administration, containing the active ingredients Pseudoephedrine hydrochloride and Triprolidine hydrochloride. Pharmacologically, it is classified as a blend of a Sympathomimetic amine (Decongestant) and a First-generation Histamine H1-receptor antagonist. This dual-action structure is clinically recognized for providing distinct and separate therapeutic contributions to symptom management, offering an integrated approach not found in single-entity antihistamines.

The original formulation is typically recognized as an over-the-counter (OTC) medication in many countries. The product structure combines the two medicinal entities to achieve this integrated action: Pseudoephedrine is the decongestant component, while Triprolidine acts by competitively blocking H1 receptor sites. This design provides a comprehensive approach, distinguishing the preparation from single-entity drugs by combining these two powerful mechanisms into one unit.


How Does Actifed Generally Help? (Primary Purpose and Benefit)

The primary purpose of Actifed is to provide comprehensive symptomatic relief for upper respiratory tract disorders. This includes easing symptoms associated with allergic rhinitis, vasomotor rhinitis, and the common cold. The combination is intended for the temporary relief of symptoms due to seasonal allergies and associated nasal obstruction.

The drug’s benefit stems from two core physiological actions working concurrently. The sympathomimetic amine component promotes vasoconstriction, which serves to reduce the swelling and congestion of the nasal mucosa. Simultaneously, the antihistamine component inhibits the effects of histamine released during allergic responses, helping to mitigate symptoms like sneezing and excessive mucus production. This combination is formulated to provide synergistic support by actively reducing nasal mucosa edema and drying out the mucous membranes.

Regulatory References

  1. [MedlinePlus](https://medlineplus.gov/druginfo/meds/a682159.html)
  2. [FDA DailyMed](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a00e0a58-e42a-430c-a61f-d74c05284459)

What side effects are possible with Actifed?

Possible Side Effects and Safety Information

The medicine's safety profile is formally documented by government regulatory bodies, classifying possible adverse reactions by the body system affected and the likelihood of occurrence.

Classification Examples of Officially Listed Reactions
Common Drowsiness, somnolence, headache, dizziness, dry mouth, nervousness, and insomnia are frequently documented.
Rare/Not Known Reactions classified as rare or of unknown frequency include hallucinations (particularly in children), palpitations, hypersensitivity, and blood disorders.

Serious adverse reactions, which are significant but infrequent, are officially recognized and documented in the prescribing information. These include major events such as Hypertensive crisis, Cerebrovascular accident (stroke), and Seizures. Specific rare, severe vascular conditions, including Posterior Reversible Encephalopathy Syndrome (PRES), Reversible Cerebral Vasoconstriction Syndrome (RCVS), and Ischaemic colitis have also been reported with the sympathomimetic component.

Population and Contextual Safety Constraints

The official labeling includes safety considerations for specific populations and conditions. Older adults may be more susceptible to central nervous system effects like confusion and sedation. Children carry a risk of paradoxical excitation, characterized by excitement or restlessness; the medication is not approved for sedation in this group. Use is contraindicated in individuals with pre-existing conditions such as severe hypertension, severe coronary artery disease, or those currently using Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of stopping them, due to the documented risk of hypertensive crisis. Additionally, effects like drowsiness may be most apparent at the start of treatment, and prolonged use carries a documented risk of tolerance or dependence. The label notes that the medicine may moderately impair the ability to drive or operate machinery.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Actifed

This profile summarizes the officially documented overdose information for the combination of pseudoephedrine and triprolidine, based strictly on government regulatory documents.

Domain Official Regulatory Statements
Documented Overdose Presentations Overdose manifestations may include symptoms of both CNS stimulation (excitement, restlessness, hallucinations, tremor) and CNS depression (drowsiness, lethargy). Other signs documented in regulatory labels are hypertension, cardiac arrhythmias, hyperpyrexia, and anticholinergic effects such as difficulty with micturition.
Physiological Systems Affected (as stated in label) Central Nervous System (CNS), Cardiovascular System, Renal System, and Metabolic System.
Dose-related or Exposure-related Factors (if applicable) Overdose can lead to low serum potassium levels due to shifts in potassium.
Population-specific Overdose Notes (if applicable) Children are noted to be more susceptible to hallucinations, nightmares, and paradoxical excitation. The elderly are documented as more prone to confusion and exaggerated neurological anticholinergic effects.
Emergency-response statements (as written in official documents) Treatment is supportive and symptomatic only. Specific documented procedures for management include maintaining respiration, controlling convulsions, and potentially using acid diuresis or dialysis for elimination.
When immediate medical help is required (label-derived phrasing only) Seek immediate medical attention or get emergency help at once. Immediate assistance is required if severe manifestations occur, such as sudden severe headache, confusion, seizures, and/or visual disturbances.

Overdose Classifications (High-Level)

Classification Aspect Regulatory Basis Statement
Severity classification (as defined in official documents) The potential for severe, life-threatening outcomes, including coma, convulsions, hypertensive crisis, and intracranial haemorrhage, is officially documented.
Regulatory basis (EMA / FDA / etc.) Information derived from government-authorized prescribing information.
Overdose-context constraints (as defined in official documents) No specific antidote is known; management is directed towards the specific symptoms presented.

Resulting Overdose Structure

Official Overdose Statements:

  • Overdose may present with signs of both CNS excitement and CNS depression, including hallucinations, restlessness, drowsiness, or lethargy.
  • Severe outcomes include documented risks of convulsions, hypertensive crisis, cardiac arrhythmias, and intracranial haemorrhage.
  • Immediate medical attention is required upon suspicion of overdose or the onset of severe symptoms like sudden severe headache or seizures.
  • Management is supportive and symptomatic and includes specific procedures such as maintaining respiration and using acid diuresis or dialysis for elimination.

Connection to the overall overdose profile: The regulatory profile defines the overdose risk based on the potential for severe cardiovascular and neurological crises, reflecting the combined effects of the active components. This profile explicitly mandates that individuals must seek urgent medical assistance for specific severe symptoms, and it details the necessary supportive measures for treatment, confirming that management focuses exclusively on symptom control since no specific antidote is known.

Therapeutic Uses of Actifed

What Actifed Treats: Main Uses and Benefits

The primary therapeutic role of Actifed is to provide focused, integrated symptomatic relief across key domains of upper respiratory tract discomfort, which may cluster during acute illness or allergy flare-ups.

The combination is relevant for the management of upper respiratory tract conditions, including allergic rhinitis, vasomotor rhinitis, and the common cold. This medication is commonly applied in clinical contexts marked by symptoms related to inflammatory or irritative states.

Relief for Allergic Rhinitis and Hay Fever Symptoms

This medication is commonly applied for symptoms associated with seasonal or perennial allergic rhinitis. It helps address symptom clusters that include sneezing, itchy eyes/nose/throat, symptoms that create noticeable physiological strain (lacrimation), and runny nose. The support in this domain is relevant for managing symptoms that interfere with daily comfort caused by environmental sensitivities.

“The primary benefit is offering symptomatic relief that helps patients cope more steadily with difficult episodes caused by upper respiratory distress.”

Easing Nasal Congestion and Obstruction

Actifed is relevant in situations where symptoms include noticeable physiological strain from nasal obstruction and congestion, such as during the common cold or related sinus discomfort. It is relevant for easing symptoms related to nasal obstruction and congestion, offering symptomatic support that contributes to improved day-to-day comfort and stability, and contributes to improved comfort during periods of heightened symptoms.

Dual-Action Support for Acute Cold Manifestations

The preparation is used to moderate the distressing combination of symptoms seen in acute upper respiratory tract disorders. It contributes to easing the overall symptom load by supporting relief across both congestion and secretory symptom domains, providing supportive relief when the symptoms of illness intensify and temporarily interfere with normal function.


Quick Fact: Therapeutic Focus

Actifed is commonly used for managing conditions characterized by periods of heightened symptoms that involve the dual manifestation of nasal congestion and rhinorrhea (runny nose).

Regulatory References

  1. HPRA Summary of Product Characteristics

Eligibility and Restrictions for Use

This section outlines the official population eligibility for Actifed (Pseudoephedrine/Triprolidine), based strictly on regulatory labeling.

Contraindications (Must Not Use)

Category Restriction
Cardiovascular/Metabolic Severe or uncontrolled hypertension, severe coronary artery disease, diabetes mellitus, hyperthyroidism, phaeochromocytoma.
Pharmacological History Use of MAO Inhibitors within the preceding 14 days, or concomitant use with beta-blockers or other sympathomimetic decongestants.
Other Conditions Severe renal impairment or kidney failure, closed-angle glaucoma, and known hypersensitivity to the ingredients.

Age and Special Population Status

Population Eligibility Status
Adults (12+ Years) Permitted for use under standard labeled conditions.
Children Contraindicated in children under 12 years (Tablets) and under 6 years (Syrup).
Pregnancy/Lactation Not recommended; use is not established, and active ingredients are known to be excreted in breast milk.

Use with Caution (Conditional Eligibility)

Caution is advised in populations with mild to moderate renal impairment, severe hepatic impairment, prostatic hypertrophy, and certain respiratory conditions such as acute or chronic asthma, which necessitate prior consultation with a physician.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes only the officially documented interaction patterns for Actifed (Pseudoephedrine and Triprolidine) as stated in government regulatory labeling.

1. Formal Contraindications

Co-administration is strictly prohibited with certain medicinal products due to the risk of severe interaction:

  • Monoamine Oxidase Inhibitors (MAOIs): Concurrent use is contraindicated and a 14-day separation period is required after the MAOI is discontinued before Actifed administration. This restriction is based on the risk of hypertensive crisis.
  • Sympathomimetic Agents: Other sympathomimetics, including decongestants, appetite suppressants, and amphetamine-like psychostimulants, are also contraindicated due to additive pressor effects.
  • Beta-Blockers: These are listed as a contraindicated combination in official documents.

2. Pharmacodynamic Interaction Risks

The product carries risks of additive effects, primarily derived from its two active components:

  • CNS Depressants and Alcohol: The Triprolidine component may enhance the sedative effects of alcohol, sedatives, tranquilizers, hypnotics, and opioid analgesics. Patients are officially instructed to avoid alcoholic beverages.
  • Cardiovascular Agents: Pseudoephedrine may partially reverse the hypotensive action of certain antihypertensives (e.g., Methyldopa). Co-administration with Halogenated Anaesthetic Agents (e.g., Halothane) may provoke or worsen ventricular arrhythmias.
  • Anticholinergic Potentiation: Combining with anticholinergic drugs can potentiate effects such as tachycardia and urinary retention.
  • Population-Specific Note: Regulatory documents note that the elderly population may be more susceptible to confusion when this medication is used with other Central Nervous System depressants.

Mechanism of Action

Vascular Tone Modulation via Adrenergic Agonism

The decongestant component, Pseudoephedrine, engages the sympathetic nervous system by acting on alpha1-adrenergic receptors to induce vasoconstriction in the nasal and sinus lining. This molecular action physically reduces the volume of blood and tissue fluid (edema) in the nasal mucosa, directly leading to the physiological effect of diminished mucosal volume and increased airway conductance.


Blockade of Histaminergic and Cholinergic Signals

The antihistamine component, Triprolidine, competitively blocks Histamine H1 receptors to prevent the inflammatory mediator histamine from increasing capillary permeability and nerve stimulation. Additionally, it engages in antagonism of muscarinic receptors, which suppresses the activity of exocrine glands. This dual blockade limits fluid leakage into tissues and reduces glandular secretions, contributing to the resulting physiological effect of reduced fluid secretion.


Integrated Dual-Pathway Modulation

The drug’s combined mechanism establishes simultaneous modulation of two core processes: it addresses existing vascular engorgement via the adrenergic pathway while inhibiting inflammation-driven fluid leakage and secretion via the histaminergic and cholinergic pathways. This integrated approach targets distinct biological drivers, resulting in a convergence of physiological consequences that includes diminished mucosal volume and decreased glandular output.

Dosage and Administration Information

Instruction Map: How to use Actifed — Official Administration Guidelines

The administration of Actifed is established as an oral medication, adhering to specific dosage limits. Use is restricted to a short-term, intermittent pattern.

Administration Scope

Instruction Detail
Route of administration Strictly Oral administration only.
Dosing schedule (Adults 12+ years) One tablet (60 mg/2.5 mg) OR 10 ml of syrup (60 mg/2.5 mg equivalent) per dose.
Frequency and Timing Doses are administered every 4 to 6 hours, as needed. A minimum 4-hour interval must separate doses.
Maximum Daily Dose Not more than 4 doses (tablets or 10 ml doses) should be administered in any 24-hour period.
Preparation requirements (Syrup) The syrup bottle must be shaken thoroughly before use. The formulation may be diluted 1:1 or 1:3 with Syrup BP.
Age-group administration rules Children 6–11 years are administered a reduced 5 ml syrup dose up to 3 times per 24 hours. Use in children under 6 years is generally contraindicated.
Course duration / cycle information The medicine is designated for short-term use. Administration should not exceed 5 consecutive days for children 6–11 years. Users are advised to seek medical review if use exceeds 7 days.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Oral administration (Liquid or Solid).
Frequency pattern As-needed (PRN), intermittent dosing with a fixed 4-hour minimum interval.
Use-context constraints Defined as a short-term course of use with strict maximum daily limits.

Connection to the overall use protocol

The official protocol establishes a rigid, intermittent use pattern based on defined unit doses for tablets and syrup. The medicine is limited to a 4- to 6-hour dosing frequency and a maximum total daily intake, ensuring the medication adheres to the established framework for short-duration administration.

Recent Clinical Evidence

Research Evidence: Overview of Clinical Studies for Actifed (Pseudoephedrine and Triprolidine)

This section provides an overview of the types of scientific research and clinical studies that exist for this specific combination medicine, focusing strictly on the evidence landscape and regulatory record. It is not intended to provide medical advice, dosing, or treatment recommendations.


Evidence for Use in Allergic Rhinitis (Hay Fever)

The research base for the Pseudoephedrine and Triprolidine combination in allergic rhinitis includes controlled clinical trials. These studies, often designed as Double-Blind, Parallel, Placebo-Controlled Studies, was studied for its application in patients with seasonal or perennial allergic rhinitis and related symptoms.

Researchers examined outcomes related to physical discomfort, monitoring changes in both the symptoms associated with congestion (like nasal obstruction) and symptoms associated with histamine release (like sneezing and rhinorrhea). Findings describe patterns observed in these studies, where measurements of symptom change were reported across the observed populations, and research describes changes measured during the short study period. The evidence contributes to understanding symptom patterns in conditions characterized by periods of heightened symptoms.

What remains uncertain is the long-term application; evidence for continuous, sustained use over long allergy seasons is limited, and the follow-up durations were limited, focusing on acute flare-ups.


Evidence for Use in the Common Cold

Research has explored episodic or acute changes in symptoms related to its use. Studies focusing on episodes where symptoms become more noticeable primarily used short-term Randomized Controlled Trials (RCTs) that evaluated adult and older adolescent populations presenting with acute cold symptoms.

The studies explored outcomes related to systemic or functional imbalance, including measures of daily functioning or activity level and changes in signs like nasal discharge. Findings describe patterns observed in studies conducted during periods of increased symptom activity. While research describes changes measured during the study period, the studies only monitored responses over defined, short time intervals, such as a few days to one week.

The evidence is limited to research observing responses over defined time intervals. Comparative evidence is lacking that directly addresses the unique contribution of the combination versus other multi-ingredient cold remedies, and findings were mixed or heterogeneous across the broader research landscape.


Evidence for Use in Vasomotor Rhinitis

The evidence specifically for the Pseudoephedrine/Triprolidine combination in vasomotor rhinitis (a non-allergic form of rhinitis) is limited, particularly compared to the evidence base for allergic rhinitis.

Data show patterns related to non-specific rhinitis; research is largely derived from studies on other rhinitis types where outcomes describing episodic or acute changes in nasal congestion were measured. Vasomotor rhinitis is a condition where symptoms may vary in intensity. Research focusing on this specific etiology remains limited.

For this indication, certainty remains low. Data for certain groups remain insufficient, with the evidence often inferred from the known pharmacological activity of the components rather than specific, targeted clinical data for this population.


Long-Term Studies and Follow-up Duration

Clinical research for this fixed-dose combination has primarily been applied in studies examining short-term or episodic symptom patterns, aligning with research scenarios involving episodic or acute changes.

The original controlled trials used in regulatory evaluations employed limited follow-up durations, typically ranging from a few days to one or two weeks. Research provides context but not individual predictions regarding long-term use, and long-term effects are not fully established. There is limited information for long-term outcomes, and continuous, chronic use has not been systematically evaluated within the framework of controlled clinical trials to assess durability of response or patterns beyond the typical acute treatment period.


Evidence in Children and Adolescents

Research has examined the use of the Pseudoephedrine/Triprolidine combination in older adolescents, who are typically included in adult trials when they meet specific age criteria (e.g., 12 years and older). These trials monitored patient-reported outcomes describing perceived discomfort in these groups.

However, specific dedicated data for younger children remain insufficient in the primary controlled trials.


Research Gaps and Areas of Uncertainty

This subsection addresses areas in the evidence base where research may be limited or where findings were mixed.

  • Heterogeneity of Findings: Evidence quality varies across studies, and some older trials may use different symptom scoring systems, meaning findings were mixed in some areas.
  • Long-Term Outcomes: There is limited information regarding the effects of repeated or continuous use over extended periods, as follow-up durations were limited.
  • Subgroup Findings: Data for certain groups remain insufficient—such as those with significant comorbid conditions—meaning subgroup findings are uncertain.
  • Comparative Evidence: Comparative evidence is lacking between this combination and newer single-entity antihistamines or decongestants. Much of the regulatory evidence is derived from studies that examined the separate contributions of the two original components.

Frequently Asked Questions (FAQ)

Common questions about Actifed (FAQ)


Q: Is Actifed intended to treat a dry cough or a wet/chesty cough?

The official indication for the core Actifed combination of pseudoephedrine and triprolidine is for upper respiratory symptoms like nasal congestion, sneezing, and a runny nose. The components function as a decongestant and an antihistamine, which may relieve symptoms that are present with a cough. However, the core medicine does not contain a dedicated cough suppressant ingredient according to regulatory records.

Q: Why does the formulation of Actifed appear to be different in various countries or versions?

Differences in the product's active ingredients across international markets are often a result of varying national regulatory and legal policies. The regulatory environment is understood to have prompted changes to the product's ingredients or availability in certain markets, while the original formulation was maintained in others. This variation stems from legal controls over ingredients like pseudoephedrine.

Q: Is the original version of Actifed containing triprolidine still available for purchase?

The availability of the original combination of pseudoephedrine and triprolidine depends on the specific country. Regulatory documents confirm that this specific formulation remains authorized and available in certain markets, such as the UK and Ireland. However, the original combination was officially discontinued in other countries, like the United States, due to regulatory changes.

Q: Are there different versions of Actifed that have different main active ingredients?

Yes, regulatory records show that various product variants have been registered under the Actifed brand name. While the core cold and allergy product contains pseudoephedrine and triprolidine, other product line extensions may contain additional active ingredients. Examples of these additions can include a different type of decongestant or a dedicated cough suppressant.

Q: Is Actifed related to the brand name Sudafed or its generic components?

The main decongestant component in Actifed is pseudoephedrine. This is the same active ingredient found in many products sold under the brand name Sudafed. Both preparations belong to the sympathomimetic class of drugs and are officially indicated for relieving symptoms of nasal congestion.

Q: Can Actifed cause feelings of restlessness, anxiety, or jitteriness?

Official labeling lists common central nervous system side effects, including restlessness and nervousness. These effects are associated with the stimulant properties of the pseudoephedrine component. In rare instances, official product information indicates that effects such as anxiety or excitation have also been documented.

Q: What kind of vision side effects are officially associated with Actifed?

Official product information states that the medicine is contraindicated, meaning it should not be used, in individuals with closed-angle glaucoma. The antihistamine component, triprolidine, has anticholinergic properties that can potentially affect the eyes. If any unusual vision changes are experienced, official guidance is that medical advice should be sought.

Q: Can Actifed cause sleep disturbances or vivid dreams, according to product information?

Official documentation lists insomnia, a type of sleep disturbance, as a common side effect, which is linked to the decongestant component. Rare or infrequent side effects documented also include hallucinations. While official documents cite rare effects like hallucinations, which may be associated with unusual sleep patterns, user reports sometimes include experiencing vivid or unusual dreams.

Q: Is there a known risk of Actifed causing severe or rare skin reactions?

Yes, official regulatory documents note that severe skin reactions, including Acute Generalized Exanthematous Pustulosis (AGEP), have been reported with the sympathomimetic component. This reaction may involve fever and the appearance of numerous small, non-infectious pus-filled spots. It is stated in official safety information that any sudden or unexpected skin changes should be promptly evaluated.

Q: What official information is available about Actifed and issues like an enlarged prostate or difficulty urinating?

Official warnings advise caution for use in individuals with prostatic hypertrophy (an enlarged prostate). The antihistamine component has anticholinergic properties that can affect the muscles controlling urination. In susceptible individuals with a pre-existing condition, this can potentially lead to difficulty urinating or urinary retention.

Q: Can Actifed be safely combined with common over-the-counter pain relievers like paracetamol (acetaminophen)?

Official drug labels generally do not document a specific, formal interaction between the active ingredients in Actifed and paracetamol (acetaminophen). Regulatory guidance emphasizes that all product labels should be reviewed to confirm that the maximum recommended daily dose for any single ingredient is not exceeded.

Q: Is there a warning about consuming high amounts of caffeine while taking Actifed?

Actifed contains pseudoephedrine, a sympathomimetic agent that stimulates the nervous system and can raise heart rate and blood pressure. Since caffeine also has stimulant properties, official product information notes that sympathomimetic agents should be used with caution in individuals with cardiovascular risk factors, given the potential for additive effects on the heart and circulation.

Q: How long is the decongestant effect of Actifed usually expected to last?

The standard dosing instructions for the formulation recommend administering a new dose every four to six hours as needed. This dosing frequency is the time frame over which the effect of the medicine is generally accounted for in the regulatory guidelines for intermittent use.

Q: Why is the original Actifed formula kept behind the pharmacy counter in some regions?

This restriction is a government regulation mandated in many regions and is not related to the drug's safety profile for the patient. Products containing pseudoephedrine are controlled because the ingredient can be chemically diverted for use as a precursor chemical in the illicit manufacture of methamphetamine.

Q: Does Actifed contain any ingredients that could result in a positive anti-doping test?

Yes, official anti-doping regulations list the decongestant ingredient, pseudoephedrine, as a prohibited substance in sports. It is banned in-competition by organizations like the World Anti-Doping Agency (WADA) when the concentration in a competitor's sample exceeds a specified regulatory threshold.

Q: What types of inactive ingredients, such as dyes or sugars, are listed in Actifed products?

Regulatory documents, such as the Summary of Product Characteristics (SmPCs), formally list all inactive ingredients, which are referred to as excipients. These can include common components like lactose and magnesium stearate for tablets, and ethanol, methyl hydroxybenzoate, or coloring agents for the liquid forms.

Q: Is Actifed still widely available under its original brand name in all international markets?

No, the wide availability of the original brand name and formulation is not uniform across all international markets. Official product records show that the original product remains authorized in some regions but was officially discontinued or replaced by a different formula in other countries due to regulatory changes concerning one of its active ingredients.

How should Actifed be stored and disposed of?

The storage and disposal of Actifed are governed by official regulatory requirements to ensure product quality and public safety.

Official Storage Conditions

Actifed tablets must be stored at room temperature, typically within the range of 59 F and 86 F (15 C and 30 C). Some formulations may be strictly required to be stored below 25 C. The product must be protected from light and moisture and should be kept in its original container to maintain integrity. Liquid forms must be protected from freezing.

Child Safety and Disposal

The medicine is required to be kept out of the sight and reach of children at all times. Regarding disposal, the official instruction is to discard any unused or expired product in accordance with local requirements. In many regions, this specifically means the medicine should not be disposed of via wastewater or household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Actifed found in:

A-Z Index: